

DECLARATION FORM ON NOTHING TO  
DECLARE OR NOTHING NEW TO DECLARE

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2 (i)		
A, part 2 (ii)		
A, part 2 (iii)		
B (i)		
B (ii)	<b>X</b>	
C		
D	<b>X</b>	
E		
F		<b>X</b>
G		

Date: 15 April 2008

State Party to the Convention: GERMANY

## Exchange of data on research centres and laboratories

**1. Name(s) of facility:**

Bernhard-Nocht-Institut für Tropenmedizin

**2. Responsible public or private organization or company:**

Free and Hanseatic City of Hamburg

**3. Location and postal address:**

Bernhard-Nocht-Straße 74  
D-20359 Hamburg

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:**

Free and Hanseatic City of Hamburg, Federal Republic of Germany and Federal States;  
one research contract funded by Federal Ministry of Defence,  
one research contract funded by Federal Ministry of the Interior

**5. Number of maximum containment units within the research centre and/or laboratory, with the indication of their respective size (m<sup>2</sup>):**

one maximum containment unit, approx. 70 m<sup>2</sup>

**6. If no maximum containment unit, indicate highest level of protection:**

n.a.

**7. Scope and general description of activities, including type(s) of micro organisms and/or toxins as appropriate:**

Diagnosis of and research on viruses causing hemorrhagic fevers (Lassa, Ebola, Marburg, Hanta)  
Development of methods for the detection of Dengue and Arena viruses, Monkey pox, Crimean-Congo fever

### Exchange of data on research centres and laboratories

**1. Name(s) of facility:**

Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health

**2. Responsible public or private organization or company:**

Federal Ministry of Food, Agriculture and Consumer Protection

**3. Location and postal address:**

Südufer 10  
D-17493 Greifswald - Insel Riems

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:**

Federal Ministry of Food, Agriculture and Consumer Protection

**5. Number of maximum containment units within the research centre and/or laboratory, with the indication of their respective size (m<sup>2</sup>):**

three maximum containment units, approx. 190 m<sup>2</sup>,  
(FMD laboratory with effluent treatment, negative pressure and HEPA filters to protect the environment according to FAO standards, no equipment for the protection of staff, therefore unsuitable for work with human pathogens)

**6. If no maximum containment unit, indicate highest level of protection:**

n.a.

**7. Scope and general description of activities, including type(s) of micro organisms and/or toxins as appropriate:**

Diagnosis of and research on animal diseases  
Veterinary medicine: mechanisms of pathogenesis, vaccines, diagnosis of Foot and mouth disease, Bovine spongiform encephalopathy, African swine fever, Classical swine fever and other animal diseases caused by viruses

**Note:** The laboratory at D-72076 –Tübingen, reported formerly under the name Bundesforschungsanstalt für Viruskrankheiten der Tiere in the past CBMs has been moved to the a.m. location and been renamed under the a.m. institute name.

## Exchange of data on research centres and laboratories

**1. Name(s) of facility:**

Institut für Virologie der Philipps Universität Marburg

**2. Responsible public or private organization or company:**

Philipps-University Marburg

**3. Location and postal address:**

Hans-Meerwein-Straße 3  
D-35043 Marburg

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence:**

State of Hessen, German Research Foundation (Deutsche Forschungsgemeinschaft), Federal Ministry of Education and Research, European Union, Federal Ministry of Defence

**5. Number of maximum containment units within the research centre and/or laboratory, with the indication of their respective size (m<sup>2</sup>):**

two maximum containment units, 110 m<sup>2</sup> each

**6. If no maximum containment unit, indicate highest level of protection:**

n.a.

**7. Scope and general description of activities, including type(s) of micro organisms and/or toxins as appropriate:**

Basic research on Marburg virus, Ebola virus, Lassa virus, Nipah Virus and SARS-Corona Virus.  
Diagnostic services in surveillance of Class 4 - viruses and smallpox virus

## National Biological Defence Research and Development Program Declaration

1) Is there a national program to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere?

Activities of such program would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

**YES**

If the answer is YES, complete Form A, part 2 (ii) which will provide a description of the program.

## National Biological Defence Research and Development Program

### II: Description

- 1. State the objectives and funding of the program and summarize the principal research and development activities conducted in the program.**

Federal Ministry of Defence :

The RD activities of the national program include: prophylaxis, diagnostic techniques, sampling and detection techniques, toxinology, decontamination and physical protection.

Summaries and objectives of all research and development projects in the field of Medical NBC Defence are published on the Internet under [www.bundeswehr.de](http://www.bundeswehr.de) .

Federal Ministry of Interior:

A B-Task Force pilot project is conducted with focus on the development of rapid detection systems for B agents. Within the scope of the project is the development of real time detection systems based on the polymerase chain reaction (PCR) and the evaluation of the PCR assays for high throughput screening tests. All investigations were accomplished at the Bernhard-Nocht-Institut Hamburg (BNI) and its facilities (see Form A, part I) . The project was completed in November 2007.

- 2. State the total funding for the program and its source.**

Federal Ministry of Defence:

The total funding in 2007 was approx. 11,4 Mio Euro.

The program is funded by the Federal Ministry of Defence.

Federal Ministry of Interior:

The funding in 2007 for the B-Task Force project Hamburg was approx. 44.000,00 €.

The program is funded by the Federal Office for Civil Protection and Disaster Assistance.

- 3. Are aspects of this program conducted under contract with industry, academic institutions, or in other non-defence facilities?**

Yes

- 4. What proportion of the total funds for the program is expended in these contracted or other facilities?**

Federal Ministry of Defence:

approx. 32 percent

Federal Ministry of Interior:

approx. 100 percent

- 5. Summarize the objectives and research areas of the program performed by contractors and in other facilities with the funds identified under para 4.**

Federal Ministry of Defence:

The objective of the contracted activities is to provide pertinent expertise and hardware to the Federal Ministry of Defence for the improvement of the B-defence capabilities. The research areas are the same as mentioned above under # 1.

The Federal Ministry of Interior:


The objective of the contracted activities is the development of a rapid detection system to be able to react as fast as possible in case of a bioterroristical assault or casualty to minimise the threatening effect on human population and economy.

**6. Provide a diagram of the organisational structure of the program and the reporting relationships (include individual facilities participating in the program).**

The Federal Ministry of Interior:

The Federal Office for Civil Protection and Disaster Assistance authorizes facilities like the Bernhard-Nocht-Institute in accordance with their expertise for the development of new real time detection systems for the identification of B-agents and organisms with high impact on public health.

The Federal Ministry of Defence:



\* Surgeon General coordinates all biodefence R + D activities of the Bundeswehr

**7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development program, within the territory of the reporting State, or under its jurisdiction or control anywhere.**

# Germany

## Form A, part 2 (iii)

### National Biological Defence Research and Development Program

1. **What is the name of the facility?**

ABC- und Selbstschutzschule der Bundeswehr  
(NBC-Defence and Self-protection School of the Bundeswehr)

2. **Where is it located?**

D-87527 Sonthofen/Allgäu, Mühlenweg 2  
(47°31 north, 10°17 east)

3. **Floor area of laboratory areas by containment level:**

BL 2	270 m <sup>2</sup>
BL 3	--
BL 4	--
Total Laboratory Floor Area	270 m <sup>2</sup>

4. **The organisational structure of the facility:**

The workload of the Biology Section of the facility is approx. 95 percent in B-defence and 5 percent in environmental protection. The following personnel figures cover the total strength for both working areas because of the engagement of some of the personnel in both areas.

I) **Total number of personnel:** 4

II) **Division of personnel:**  
Military -  
Civilian 4

III) **Division of personnel by category:**  
Scientists 1  
Engineers -  
Technicians 2  
Admin. and support staff 1

IV) **Represented scientific disciplines:**  
Parasitology, toxicology, microbiology, veterinary medicine

V) **Contractor staff:** 0



VI) **Source of funding:** Federal Ministry of Defence

VII) **Funding levels for the following program areas:**

The funding for the 95 percent share for personnel, consumable items and equipment in 2007 was approx. 0,2 million €

Development	25 %
Test and Evaluation	15 %
Education and Training	60 %

VIII) **Publication policy:**

Results will be published primarily in reports to the Federal Office for Military Technology and Procurement and to the Federal Ministry of Defence and will be presented in scientific meetings.

IX) **Lists of public available papers and reports resulting from the work during the previous 12 months:**

none

5. **Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Conceptual development of biological defence in the Bundeswehr
- b. Initiation of and participation in the development of biological defence material and equipment; drafting of operational requirements
- c. Review and establishment of detection methods for pathogens and toxins suitable for military use
- d. Training of NBC defence personnel (theory and practice) including familiarisation with the handling of vectors, microorganisms and toxins
- e. Training support for non-military government authorities
- f. Training support for military personnel of other states
- g. Initiation and expert monitoring of studies in the field of biological defence
- h. Drafting of joint publications for biological defence

The current program covers R I and R II organisms, inactivated material of pathogens R III and RIV, insects and ticks as well as high and low-molecular toxins; no work has been done with active viruses.

No outdoor studies of biological aerosols.

# Germany

Form A, part 2 (iii)

## National Biological Defence Research and Development Program

### 1. What is the name of the facility?

Institut für Mikrobiologie der Bundeswehr (Bundeswehr Institute of Microbiology)

### 2. Where is it located?

D-80937 München, Neuherbergstraße 11  
(48°12' north, 11°34' east)

### 3. Floor area of laboratory areas by containment level:

BL 2	1258 m <sup>2</sup>
BL 3	67 m <sup>2</sup>
BL 4	-- m <sup>2</sup>
Total Laboratory Floor Area	1325 m <sup>2</sup>

### 4. The organisational structure of the facility:

I) **Total number of personnel:** 63

II) **Division of personnel:**  
Military 36  
Civilian 27

III) **Division of personnel by category:**  
Scientists 20  
Technicians 38  
Admin. And support staff 5

IV) **Represented scientific disciplines:**

Medicine, veterinary medicine, microbiology, virology, bacteriology, immunology, molecular biology, epidemiology, laboratory medicine

V) **Contractor staff:** 2

VI) **Source of funding:** Federal Ministry of Defence

VII) **Funding levels for the following program areas:**

The funding for personnel, consumable items and equipment in 2007 was approx. 5 million €.

Research	40 %
Development	25 %
Test and Evaluation	25 %
Education and Training	10 %

VIII) **Publication policy:**

Results are published in scientific journals as well as in reports to the Federal Ministry of Defence and will be presented in national and international scientific meetings.

IX) **Lists of public available papers and reports resulting from the work during the previous 12 months:**

see Annex 1

**5. Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Research, development and evaluation of approaches for the rapid detection, identification and differentiation and typing of *Orthopoxviruses*, *Alpha-*, *Flavi-*, *Bunyaviruses* using polyclonal and monoclonal antibodies and real-time-PCR
- b. Research, development and evaluation of approaches for the rapid detection, identification and differentiation of *Cocciella*, *Burkholderia*, *Yersinia*, *Brucella*, *Bacillus* and *Francisella spp.* using polyclonal and monoclonal antibodies, biochemical methods and real-time-PCR
- c. Production of polyclonal and monoclonal antibodies and production of test kits for the immunodiagnosis of relevant infections
- d. Studies of the epidemiology, immunopathogenesis and immune response against *Francisella tularensis*, *Bacillus spp.*, *Burkholderia spp.*, *Brucella spp.* and *Yersinia spp.*, resp.

The current program covers pathogen R I, R II and R III organisms.

No outdoor studies of biological aerosols have been conducted.

## National Biological Defence Research and Development Program

**1. What is the name of the facility?**

Wehrwissenschaftliches Institut für Schutztechnologien – ABC-Schutz  
(Federal Armed Forces Scientific Institute for Protection Technologies - NBC-Protection)

**2. Where is it located?**

D-29633 Munster/Oertze, Humboldtstr.  
(53°00 North, 10°08 East)

**3. Floor area of laboratory areas by containment level:**

BL 2	520 m <sup>2</sup>
BL 3	360 m <sup>2</sup>
BL 4	----- m <sup>2</sup>
Total Laboratory Floor Area	880 m <sup>2</sup>

**4. The organisational structure of the facility:**

The workload of the Biology Section of the facility is approx. 90 percent in B-defence and approx. 10 percent in bio-analytics. The following personnel figures cover the total strength for both working areas because of the engagement of some of the personnel in both areas.

I) **Total Number of personnel:** 35

II) **Division of personnel Civilian** 35

III) **Division of personnel by category**

Scientists	8
Engineers	6
Technicians	17
Admin. and support staff	4

IV) **Represented scientific disciplines:**

Biology, biochemistry, immunology, molecular biology, bacteriology, mycology, virology, toxicology, toxinology, biotechnology, pathology, environmental toxicology, ecology, veterinary medicine, biotechnology

V) **Contractor staff:** 0

VI) **Source of funding:**  
Federal Ministry of Defence

VII) **Funding levels for the following program areas:**

The funding for the 90 percent share for personnel, consumable items and equipment in 2007 was approx. 2 Mil €

Research	40 %
Development	30 %
Test and Evaluation	30 %

**VIII) Publication policy**

Results will be published primarily in reports to the Federal office for Military Technology and Procurement and to the Federal Ministry of Defence.

**IX) Lists of publicly available papers and reports resulting from the work during the previous 12 months:**

Laue MB, Niederwöhrmeier, Bannert N (2007) Rapid diagnostic thin section electron microscopy of bacterial endospores. *J. Microbiol. Methods* 70 (1): 45-54. Epub Mar 30

Köhne S, Laumann S, Russmann, H (2007) Detektion biologischer Kampfstoffe im Einsatz. *Europäische Sicherheit*, März 2007

Niederwöhrmeier B, Derakshani N, Uelpenich G, Finke, EJ, König, M (2007) Probenahme und initiale Bewertung bei biologischen Lagen. In „Biologische Gefahren I Handbuch zum Bevölkerungsschutz, 3rd edition (Robert-Koch-Institut, Bundesamt für Bevölkerungsschutz und Katastrophenhilfe eds), ISBN 3-939347-06-X

Bannert N, Biederbick W, Brockmann S, Busch U, Dorner BG, Dorner MB, Finke EJ, Grunow R, Jacob D, Nattermann H, Niederwöhrmeier B, Niedrig M, Pauli G, Sasse J (2007) Diagnostik von Infektionserregern und Toxinen. In „Biologische Gefahren I Handbuch zum Bevölkerungsschutz, 3rd edition (Robert-Koch-Institut, Bundesamt für Bevölkerungsschutz und Kathastrophenhilfe eds), ISBN 3-939347-06-X

Richardt A, Russmann H (2007) Biological warfare agents: detection and decontamination. *Safety & Security International IV/07*, III-IV

Yacoub-George E, Hell W, Meixner L, Wenninger F, Bock K, Lindner P, Wolf H, Kloth T, Feller KA (2007) Automated 10-channel capillary chip immunodetector for biological agents detection. *Biosens. Bioelectron.* 22, 1368-1375

**5. Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Development of early-warning systems permitting non-specific identification of toxins, micro organisms and viruses.
- b. Development of equipment and procedures for rapid and accurate identification of toxins and pathogenic agents in samples of air, water, soil, vegetation (sensor-equipment, collectors, detection kits)
- c. Development of procedures for disinfection and decontamination
- d. Anthrax and toxin laboratory analysis with suspect samples

The current program covers non-human pathogen R I and pathogenic R II and R III organisms as well as low-molecular weight toxins; no work has been done with active R III viruses.

Outdoor studies were performed with commercial “Turex” (*Bacillus thuringiensis var. aizawai*) as a simili for biological aerosols.

**National Biological Defence Research  
and Development Program**

**1. What is the name of the facility?**

Zentrales Institut des Sanitätsdienstes der Bundeswehr Kiel, Laborgruppe Spezielle Tierseuchen- und Zoonosendiagnostik (Central Institute of the Bundeswehr Medical Service Kiel, Laboratory for Infectious Animal Diseases and Zoonosis).

The laboratory was located until June 2007 in the Wehrwissenschaftliches Institut für Schutztechnologien – ABC-Schutz (Federal Armed Forces Scientific Institute for Protection Technologies - NBC-Protection)

In June 2007 it was transferred to the Zentrales Institut des Sanitätsdienstes der Bundeswehr in Kiel-Kronshagen. The work carried out in the facility is the same.

**2. Where is it located?**

D-24119 Kronshagen, Kopperpähler Allee 120.  
(54°20'24'' north, 10°05'37'' east)

**3. Floor area of laboratory areas by containment level:**

BL 2	274 m <sup>2</sup>
BL 3	47 m <sup>2</sup>
BL 4	--

Total Laboratory Floor Area 321 m<sup>2</sup>

**4. The organisational structure of the facility:**

The workload is 70 percent in the diagnosis of infectious animal diseases and zoonoses and 30 percent in B-defence.

I) **Total number of personnel:** 5

II) **Division of personnel:**  
Military 3  
Civilian 2

III) **Division of personnel by category:**  
Scientists 2  
Technicians 3

IV) **Represented scientific disciplines:**  
veterinary medicine, microbiology, virology, bacteriology, parasitology, molecular biology, immunology

V) **Contractor staff:** 0

VI) **Source of funding:** Federal Ministry of Defence

VII) **Funding levels for the following program areas:**

The funding for consumable items and equipment in 2007 was approx. 0,45 Mio €

Development	25 %
Test and Evaluation	30 %
Diagnosis	40 %
Education and training	5 %

VIII) **Publication policy:**

Results will be published primarily in reports to the Federal Ministry of Defence and in journals for military medicine or technology

IX) **Lists of public available papers and reports resulting from the work during the previous 12 month:**

In 2007 no results were published in journals.

**5. Brief description of the biological defence work carried out at the facility, including types of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols:**

- a. Development and evaluation of diagnostic systems permitting specific identification of microorganisms, viruses and toxins
- b. Development of test kits for use in a deployable containerised field laboratory
- c. Diagnosis of zoonoses i.e. Q-fever, anthrax, rabies, avian influenza and other influenza viruses
- d. Diagnosis of infectious animal diseases, especially swine fever
- e. Diagnosis of food and waterborne threats, i.e. *Vibrio cholerae* and Norovirus
- f. Evaluation of test kits for the detection of *Clostridium botulinum* toxins
- g. Development of test kits for the detection of ricin

The current program covers pathogen R I, R II and R III organisms.

No outdoor studies of biological aerosols.

## Publications

### Bundeswehr Institute of Microbiology

2007

#### Peer Reviewed Publications

1. **Essbauer S**, Schmidt-Chanasit J, Madeja EL, Wegener W, Friedrich R, Petraityte R, Sasnauskas K, Jacob J, Koch J, **Dobler G**, Conraths FJ, **Pfeffer M**, Pitra C, Ulrich RG (2007). Nephropathia epidemica in metropolitan area, Germany. *Emerging Infectious Diseases* **13**(8), 1271-1273
2. **Essbauer S**, **Meyer H**, **Porsch-Özcürümez M**, **Pfeffer M** (2007). Long-lasting stability of vaccinia virus (Orthopoxvirus) in food and environmental samples. *Zoonoses and Public Health* **54**, 118-124
3. **Pfeffer M**, **Dobler G**, Hassler D (2007). Ockelbo-Krankheit: Stechmücken-übertragene Polyarthritits in Skandinavien. *Deutsche Medizinische Wochenschrift* **132**(13), 656-658
4. **Tomaso H**, Thullier P, **Seibold E**, Guglielmo V, **Buckendahl A**, Rahalison L, Neubauer H, **Scholz HC**, **Splettstoesser WD** (2007). *In vitro* evaluation of hand-held test kits, immunofluorescence microscopy, ELISA, and flow cytometric analysis for the rapid presumptive identification of *Yersinia pestis*. *Journal of Clinical Microbiology* **45**(10): 3404-7
5. **Tomaso H**, **Scholz HC**, Neubauer H, Al Dahouk S, **Seibold E**, Landt O, Forsman M, **Splettstoesser WD** (2007). Real-time PCR using hybridization probes for the rapid and specific identification of *Francisella tularensis* subspecies *tularensis*. *Molecular and Cellular Probes* **21**: 12-16
6. **Tomaso H**, **Scholz HC**, Al Dahouk S, **Splettstoesser WD**, Neubauer H, **Pfeffer M**, Straube E (2007). Einsatzrelevanz der PCR als diagnostisches Verfahren (Mission oriented diagnostic real-time PCR) *Wiener Klinische Wochenschrift* **118** [Suppl 3]: 26-32
7. **Seibold E**, Bogumil R, Vorderwuelbecke S, Al Dahouk S, **Buckendahl A**, **Tomaso H**, **Splettstoesser WD** (2007). The improved use of Surface Enhanced Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry (SELDI TOF MS) to differentiate *Francisella tularensis* to the level of subspecies and individual strains. *FEMS Immunology and Medical Microbiology* **49**(3): 364-73
8. **Splettstoesser WD**, Mätz-Rensing K, **Seibold E**, **Tomaso H**, Al Dahouk S, Grunow R, **Essbauer S**, **Buckendahl A**, **Finke EJ**, Neubauer H (2007). Re-emergence of *Francisella tularensis* in Germany: fatal tularaemia in a colony of semi-free-living marmosets (*Callithrix jacchus*). *Epidemiology and Infection* **135**(8): 1256-65
9. **Wölfel R**, Paweska JT, Petersen N, Grobbelaar AA, Leman PA, Hewson R, Georges-Courbot



- MC, Papa A, Günther S, and Drosten C (2007). Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients. *Emerging Infectious Diseases* **13**(7), 1097-1100
10. Grunow R, **Porsch-Özcürümez M, Splettstoesser W, Buckendahl A**, Hahn U, Beyer W, Böhm R, Huber M, vd Esche U, Bessler W, **Frangoulidis D, Finke EJ** (2007). Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. *Vaccine* **25**(18):3679-83
  11. Al-Ziabi M.O, Nishikawa H, and **Meyer H.** (2007). The first outbreak of camel pox in Syria. *Journal of Veterinary Medical Science* **69**, 541-543
  12. Rimoin AW, Kisalu N, Kebela-Ilunga B, Mukaba T, Wright LL, Formenty P, Wolfe ND, Loshima Shongo R, Tshioko F, Okitolonda E, Muyembe JJ, Ryder RW, **Meyer H** (2007). Endemic Human Monkeypox, Democratic Republic of Congo, 2001 – 2004. *Emerging Infectious Diseases* **13**, 934-937
  13. Al Dahouk S, Nöckler K, **Scholz HC, Pfeffer M**, Neubauer H, **Tomaso H** (2007). Evaluation of genus- and species-specific real-time PCR assays for the identification of *Brucella* spp. *Clinical Chemistry and Laboratory Medicine* **45**; 1464-1470
  14. Kämpfer P, Citron DM, Goldstein, EJC, **Scholz, HC** (2007). Difficulty in the identification and differentiation of clinically relevant *Ochrobactrum* species. *Journal of Medical Microbiology* **56**: 1571-1573
  15. Neubauer H, Sprague LD, Joseph M, **Tomaso H**, Al Dahouk S, Witte A, Kinne J, Hensel A, Wernery R, Wernery U, **Scholz HC** (2007). Development and clinical evaluation of a PCR assay targeting the metalloprotease gene (*mprA*) of *B. pseudomallei*. *Zoonoses and Public Health* **54**: 44-50
  16. Brumme S, Arnold T, Sigmarsson H, Lehmann J, **Scholz HC**, Hardt WD, Hensel A, Truyen U, Roesler U (2007). Impact of *Salmonella Typhimurium* DT104 virulence factors *invC* and *sseD* on the onset, clinical course, colonization patterns and immune response of porcine salmonellosis. *Veterinary Microbiology* **124**: 274-85
  17. Al Dahouk S, Le Flèche P, Noeckler K, Jacques I, Grayon M, **Scholz HC, Tomaso H**, Vergnaud G, Neubauer H. (2007). Evaluation of *Brucella* MLVA typing for human brucellosis. *Journal of Microbiological Methods* **69**(1): 137-45
  18. Mätz-Rensing K, Floto A, Schrod A, Becker T, **Finke EJ, Seibold E, Splettstoesser WD**, Kaup F.J (2007). Epizootic of Tularemia in an Outdoor Housed Group of Cynomolgus Monkeys (*Macaca fascicularis*). *Veterinary Pathology* **44**, 327-34.
  19. Olsen JS, Skogan G, Fykse EM, Rawlinson EL, **Tomaso H**, Granum PE, Blatny JM (2007). Genetic distribution of 295 *Bacillus cereus* group members based on adk screening in combination with MLST (Multilocus Sequence Typing) used for validating a primer targeting a chromosomal locus in *Bacillus anthracis*. *Journal of Microbiological Methods* **71**: 265-274
  20. Sprague L, **Tomaso H**, Mengele K, Schilling D, Bayer C, Stadler P, Schmitt M, Molls M, (2007). Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and theurokinase-type plasminogen activator receptor in human head and neck tumour cells. *Oncology Reports* **17**(5): 1259-68
  21. Schnedl J, Auer H, Fischer M, **Tomaso H**, Pustelnik TC, Mooseder G (2007). Kutane

- Leishmaniose – Import aus Belize. Wiener Klinische Wochenschrift **119** [Suppl 3]: 102-105
22. Guglielmo-Viret V, **Splettstoesser WD**, Thullier P (2007). An immunochromatographic test for the diagnosis of ricin inhalational poisoning. *Clinical Toxicology* **45**, 505-11.
  23. Hubálek Z, **Scholz HC**, Sedláček I, Melzer F, Sanogo YO, Nesvadbová J (2007). Brucellosis of the Common Vole (*Microtus arvalis*). *Vector Borne Zoonotic Diseases* **7**: 679-88
  24. Kämpfer P, **Scholz HC**, Falsen E, Busse HJ (2007). *Ochrobactrum haematophilum* sp. nov. and *Ochrobactrum pseudogrignonense* sp. nov, isolated from human clinical specimens. *International Journal Systematic and Evolutionary Microbiology* **57**: 2513-2518
  25. Kämpfer P, **Scholz HC**, Huber B, Thummes K, Busse HJ, Edward R, Moore B, Falsen E (2007). *Pseudochrobactrum kiredjiana* sp. nov. 2007. *International Journal Systematic and Evolutionary Microbiology* **57**: 755-760
  26. Panning M, Laue T, Ölschlager S, Eickmann M, Becker S, Raith S, Georges Courbot MC, Nilsson M, Gopal R, Lundkvist A, di Caro A, Brown D, **Meyer H**, Lloyd G, Kümmerer BM, Günther S, Drosten C (2007). Diagnostic Reverse-Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories. *The Journal of Infectious Diseases* **196**, 199-204
  27. Scaramozzino N, Ferrier-Rembert A, Favier A, Rothlisberger C, Richard S, Crance JM, **Meyer H**, Garin D (2007). Real-Time PCR to Identify Variola Virus or Other Human Pathogenic Orthopox Viruses. *Clinical Chemistry* **53**: 603-613
  28. Taubitz W, Cramer JP, Kapaun A, **Pfeffer M**, Drosten C, **Dobler G**, Burchard GD, Löscher T (2007). Chikungunya fever in travellers: clinical presentation and course. *Clinical Infectious Diseases* **45** Epub 2007 May
  29. Schaudien D, **Meyer H**, Grunwald D, Janssen H, Wohlsein P (2007). Concurrent Infection of a Cat with Cowpox Virus and Feline Parvovirus. *Journal of Comparative Pathology* **137**, 151-154
  30. Kampen H, Poltz W, Hartelt K, **Wölfel R**, Faulde M (2007). Detection of a questing *Hyalomma marginatum marginatum* adult female (Acari, Ixodidae) in southern Germany. *Experimental and Applied Acarology* **43**(3):227-31
  31. Ehlers B, Küchler J, Yasmum N, Dural G, Voigt S, Schmitt-Chanasit J, Jäkel T, Matuschka FR, Richter D, **Essbauer S**, Hughes DJ, Summers C, Bennett M, Stewart JP, Ulrich R (2007). Identification of novel rodent herpesviruses, including the first gammaherpesvirus of *Mus musculus*. *Journal of Virology* **81**(15):8091-100

#### Further Publications

1. **Derschum H**, Kornprobst N, Feil EC (2007). Detection strikes infection: Approved mobile biological detection. *Medical Corps International* **4**: 43-44
2. **Derschum H**, Gramsamer B, **Dobler G**, Friedewald S (2007). Prüfung der Feldtauglichkeit eines Real-time-PCR Systems am Beispiel der Schnell Diagnostik von Influenzainfektionen. *Wehrmedizinische Monatsschrift* **11**, 333-337
3. **Dobler G**, **Essbauer S**, **Pfeffer M** (2007). FSME in Bayern: Ausweitung der Endemiegebiete, Erregernachweis in Zecken, Veränderung der Viren? *Bayerisches Ärzteblatt* **62**, 188-191

4. **Dobler G** (2007). Die Japanische Enzephalitis ist in weiten Teilen Asiens endemisch. Flugmed. Tropenmed. Reisemedizin **14**(3), 146
5. **Dobler G, Pfeffer M, Friedewald S, Wölfel R, Brey R, Essbauer S** (2007). Isolierung und molekularbiologische Charakterisierung eines Frühsommer-Meningoencephalitis (FSME) Virus aus Süddeutschland. Wehrmedizinische Monatsschrift **11**, 330-333
6. **Dobler G, Essbauer S, Pfeffer M** (2007). FSME in Bayern. Bayerisches Ärzteblatt **61** (4), 188-191
7. **Essbauer S, Thomas A, Schmidt-Chanasit J, Madeja EL, Wegener W, Friedrich R, Koch J, Conraths FJ, Pfeffer M, Ulrich RG, Dobler G** (2007). Aufklärung von ungewöhnlichen Krankheitsausbrüchen: Zum Ausbruch von Puumalavirus – bedingter Nephropathia epidemica in einer deutschen Großstadt. Wehrmedizinische Monatsschrift **11**, 325-330
8. **Finke EJ, Wölfel R, Splettstoesser WD** (2007). Challenges on the diagnostics of bioterrorism related health disorders. Medical Corps International **3**: 29
9. **Friedewald S, Stiel S, Tomaso H** (2007). Mikrobiologische Forensik: Herausforderung für die Zukunft. Wehrmedizinische Monatsschrift **11**, 341-346
10. **Meyer H, Zimmermann P** (2007). Infektionen mit dem Affenpockenvirus in der Demokratischen Republik Congo 2001-2004. Wehrmedizinische Monatsschrift **11**, 314-317
11. **Pfeffer M, Dobler G** (2007). Bedeutung der Vogelgrippeviren für den Menschen. Wehrmedizinische Monatsschrift **51**(5), 106-110
12. **Splettstößer WD, Tomaso H** (2007). Die Pest im 21. Jahrhundert: Aktuelle Aspekte und wehrmedizinische Relevanz. Wehrmedizinische Monatsschrift **11**, 317-325
13. **Tomaso H, Al Dahouk S, Pfeffer M, Scholz HC** (2007). Real-time PCR Verfahren zum Nachweis bakterieller Agenzien. Wehrmedizinische Monatsschrift **11**, 337-341
14. Ulrich RG, Koch J, Schmidt-Chanasit J, Mertens M, Pelz HJ, Jacob J, Freise J, Groschup MH, Conraths FJ, **Dobler G**, Bradt K, Wegener W, **Essbauer S** (2007). 2005, ein Jahr der Hantaviren – Quo vadis ? Der Hygieneinspektor **9**(1): 61-68
15. Triebenbacher C, **Essbauer S**, Jacob J, Ulrich R (2007). Hantaviren. LWF - Waldforschung aktuell **60**(14), 66
16. Triebenbacher C, **Essbauer S**, Jacob J, Ulrich R (2007). Hantaviren – erhöhte Gefahr für die Beschäftigten im Wald? Blickpunkt Waldschutz - Bayerische Waldschutz Nachrichten, **13**, 1-4
17. Gniel D, **Dobler G** (2007). Japan Enzephalitis Impfung. Impfdialog **3**, 89-98
18. Foyse J, **Wölfel R** (2007). Hemorrhagic fever: Beware of ticks, KFOR Chronicle, Aug 2007 (8), 22

## Book Chapters

1. Feldmeier H, **Finke EJ** (2007). Wie erkennt man den Beginn einer außergewöhnlichen biologischen Lage? In: Biologische Gefahren - Handbuch zum Bevölkerungsschutz; Herausgeber: Bundesamt für Bevölkerungsschutz und Katastrophenhilfe, Seiten 94 – 107
2. Niederwöhrmeier B, Derakshani N, Uelpenich G, **Finke EJ**, König M (2007). Probennahme und initiale Bewertung bei biologischen Lagen. In: Biologische Gefahren - Handbuch zum Bevölkerungsschutz; Herausgeber: Bundesamt für Bevölkerungsschutz und Katastrophenhilfe, Seiten 131 – 148
3. Bannert N, Biederbick W, Brockmann S, Busch U, Dorner BG, Dorner MB, **Finke EJ**, Grunow R, Jacob D, Nattermann H, Niederwöhrmeier B, Niedrig M, Pauli G, Sasse J (2007). Diagnostik von Infektionserregern und Toxinen. In: Biologische Gefahren - Handbuch zum Bevölkerungsschutz; Herausgeber: Bundesamt für Bevölkerungsschutz und Katastrophenhilfe, Seiten 166 – 187
4. Fock R, **Finke EJ**, Fleischer K, Gottschalk R, Graf P, Grünewald Th, Koch U, Michels, Peters M, Wirtz A, Andres M, Bergmann H, Biederbick W, Fell G, Niedrig M, Scholz D (2007). Begriffsbestimmungen seuchenhygienisch relevanter Maßnahmen und Bezeichnungen. In: Biologische Gefahren - Handbuch zum Bevölkerungsschutz; Herausgeber: Bundesamt für Bevölkerungsschutz und Katastrophenhilfe, Seiten 391 – 409
5. Graf P, **Finke EJ**, Fleischer K, Huber H, Pfaff G (2007). Management von Ansteckungsverdächtigen: Ermittlung, Klassifizierung, Beratung und anti-epidemische Maßnahmen. In: Biologische Gefahren - Handbuch zum Bevölkerungsschutz; Herausgeber: Bundesamt für Bevölkerungsschutz und Katastrophenhilfe, Seiten 456 – 465
6. **Finke EJ** und **Frangoulidis D** (2007). B-Gefahren. In „Notfallmedizin“, Herausgeber: Scholz/Sefrin/Böttiger/Dörges/Wenzel, 2. Aufl, Thieme-Verlag, Seiten 623 – 627
7. **Frangoulidis D**, Heiser V, Landt O, **Meyer H** (2007). Low-Cost-and-Density (LCD)-Microarrays - a novel Technique for Identification and Typing of Microorganisms. In: COST B28 WG1 book of abstract 2007, 95-100
8. **Dobler G** (Hrsg.) (2007). Impfungen und Reisemedizin. Spitta Verlag 2007

## Germany

Form B (i)

### Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

#### Human Diseases (cases)

	2003	2004	2005	2006	2007
<b>Anthrax</b>	0	0	0	0	0
<b>Botulism</b>	8	6	24	7	9
<b>Brucellosis</b>	27	32	31	37	21
<b>Cholera</b>	1	3	0	1	2
<b>Glanders</b>	0	0	0	0	0
<b>Ornithosis</b>	41	15	33	25	10
<b>Plague</b>	0	0	0	0	0
<b>Q-fever</b>	386	114	416	204	82
<b>Shigellosis</b>	793	1149	1168	815	867
<b>Smallpox</b>	0	0	0	0	0
<b>Tularemia</b>	3	3	15	1	20
<b>Typhus abdominalis</b>	66	82	80	75	59
<b>Typhus fever</b>	1	0	0	0	0
<b>Viral hemorrhagic fever</b>	0	1**	1**	1*	0
<b>Yellow fever</b>	0	0	0	0	0

\* Lassa

\*\*Dengue

## Germany

Form B (i)

### Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

#### Animal Diseases (outbreaks)

	2003	2004	2005	2006	2007
African swine fever	0	0	0	0	0
Anthrax	0	0	0	0	0
Aujeszky's disease	0	0	0	0	0
Bovine Brucellosis	0	0	0	0	0
Foot and mouth disease	0	0	0	0	0
Classical swine fever of domestic pigs	1	0	0	8	0
Newcastle disease	0	0	0	0	0
Psittacosis	184	162	139	83	154
Q fever	221	150	111	96	109
Rabies (districts)	18	28	39	11	6
Rinderpest	0	0	0	0	0
Sheep pox	0	0	0	0	0
Swine vesicular disease	0	0	0	0	0
Teschen disease	0	0	0	0	0
Tularemia	0	0	0	4	6

## Exchange of Information on Published Results

In **2007** scientific papers related to research and development for prophylactic and/or protective measures against microbial and biological agents and toxins sponsored by the Federal Ministry of Defence have been published inter alia in the following journals:

Bayerisches Ärzteblatt

Biosensor and Bioelectronics

Clinical Chemistry and Laboratory Medicine

Clinical Chemistry

Clinical Infectious Diseases

Clinical Toxicology

Deutsche Medizinische Wochenschrift

Emerging Infectious Diseases

Epidemiology and Infection

Experimental and Applied Acarology

FEMS Immunology and Medical Microbiology

International Journal Systematic and Evolutionary Microbiology

Journal of Clinical Microbiology

Journal of Comparative Pathology

Journal of Veterinary Medical Science

Journal of Virology

Journal of Medical Microbiology

Journal of Microbiological Methods

Medical Corps International

Molecular and Cellular Probes

Oncology Reports

The Journal of Infectious Diseases

Vector Borne Zoonotic Diseases

Veterinary Microbiology

Veterinary Pathology

Vaccine

Wehrmedizinische Monatsschrift

Wiener Klinische Wochenschrift

Zoonoses and Public Health

# Germany

Form E

## Declaration of Legislation, Regulations and Other Measures

<b>RELATING TO MEASURES</b>	<b>LEGISLATION</b>	<b>REGULATIONS</b>	<b>OTHER</b>	<b>AMENDED SINCE LAST YEAR</b>
a) Development, production, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	NO	All pertinent legislation related to a), b), and c) is published with links to source documents on UN website: <a href="http://www.un.org/sc/1540/legisdocuments.shtml">http://www.un.org/sc/1540/legisdocuments.shtml</a>
b) Exports of microorganisms* and toxins	YES	YES	NO	
c) Imports of microorganisms* and toxins	YES	YES	NO	

\* Microorganisms pathogenic to humans, animals and plants in accordance with the Convention



**Declaration of Vaccine Production Facilities**

**A.1. Name of Facility:**

Novartis Vaccines and Diagnostics GmbH & Co. KG

**2. Location (mailing address):**

Postfach 1630  
D-35006 Marburg

**3. General description of the types of diseases covered:**

botulism (antitoxin), diphtheria, influenza, pertussis, rabies, tetanus, tick-borne encephalitis, meningococcal meningitis C

**B. 1. Name of Facility:**

GlaxoSmithKline Biologicals  
(Branch of SmithKline Beecham Pharma GmbH & Co KG)

**2. Location (mailing address):**

Zirkusstr. 40  
D-01069 Dresden

**3. General description of the types of diseases covered:**

influenza

**C.1. Name of Facility:**

IDT Biologika GmbH

**2. Location (mailing address):**

Postfach 400214  
D-06855 Dessau-Roßlau

**3. General description of the types of diseases covered:**

Smallpox (vaccinia virus vaccines), HIV (clinical trial vaccines), malaria (clinical trial vaccines), hepatitis B (clinical trial vaccines), Salmonella typhi (oral live vaccine)